News & Updates

Early administration of oral VV116 was noninferior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in individuals with mild-to-moderate COVID-19 who were at high risk for progression to severe disease, a phase III trial has shown. VV116 also had fewer safety issues than nirmatrelvir-ritonavir.

Use of adjunctive intravenous (IV) vitamin C for the management of critically ill patients with COVID-19 infection does not achieve the desired outcome of a reduction in the incidence of mortality, vasopressor requirements, Sequential Organ Failure Assessment (SOFA) scores, or ventilator settings, reports a study.

The use of sodium-glucose transporter 2 (SGLT2) inhibitors among patients with diabetes does not pose an increased risk of developing fractures as compared with dipeptidyl-peptidase 4 (DPP4) inhibitors, and this is true across estimated glomerular filtration rate (eGFR) and albuminuria categories, as shown in a study.

Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Several patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab report developing immune-related adverse events (irAEs), primarily affecting the skin, lungs, and gastrointestinal system, according to a study.